Pharmaceutical industry – Page 36
-
Business
GSK’s ViiV to buy HIV drugs from BMS
Deal hands over Bristol-Myers Squibb’s entire HIV pipeline as the company looks to quit virology research
-
Business
AstraZeneca to buy Acerta for blood cancer drug
Deal will strengthen AstraZeneca’s immunotherapy offering
-
-
-
Business
Mexico approves world’s first dengue vaccine
Sanofi’s vaccine protects children and adults against the mosquito-borne disease
-
Business
BioAtla and Pfizer to collaborate on antibody research
Two-way agreement to share technology and royalties on new cancer drugs
-
-
Business
Heptares takes on new partners for drug discovery
Firm set to receive over $1bn from research partnerships
-
Business
Pfizer to close Cambridge pain outpost
120 jobs under threat from closure of Neusentis subsidiary R&D site
-
Business
Perrigo nabs US rights to AZ Crohn’s drug
Irish generics maker evades Mylan takeover bid and expands gastroenterology portfolio
-
NewsPfizer’s response to compound fraud spotlights quality issues
‘Bosutinib isomer’ typifies threat posed by evolution of chemical supply chain
-
BusinessPfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
Business
Drug firms to share chemical compound libraries
AstraZeneca and Sanofi aim to facilitate drug discovery by swapping 210,000 proprietary chemical compounds
-
Opinion
Toeing the advertising line
Companies have to tread a little carefully when it comes to advertising prescription drugs
-
BusinessViral cancer therapy approved in the US
T-Vec is the first approved oncolytic virus, but its limited treatment scope means it is unlikely to become a blockbuster
-
BusinessPharma kickback claims lead to individual prosecutions
Warner Chilcott and Novartis face large fines for paying doctors to prescribe their drugs
-
Business
AstraZeneca to buy ZS Pharma for ion-balance drugs
$2.7 billion deal anticipates regulatory success for drug candidate under review
-
Business
Samsung to sell chemicals businesses to Lotte
Korean conglomerate Lotte will pay £1.7 billion for stake in Samsung’s chemicals businesses
-
Business
Shire to buy rare disease specialist Dyax
Deal includes an already-approved drug for angioedema and an experimental antibody treatment